Journal of Biological Chemistry
Volume 277, Issue 17, 26 April 2002, Pages 14877-14883
Journal home page for Journal of Biological Chemistry

MOLECULAR BASIS OF CELL AND DEVELOPMENTAL BIOLOGY
Novel Pathways Associated with Bypassing Cellular Senescence in Human Prostate Epithelial Cells*210

https://doi.org/10.1074/jbc.M200373200Get rights and content
Under a Creative Commons license
open access

Cellular senescence forms a barrier that inhibits the acquisition of an immortal phenotype, a critical feature in tumorigenesis. The inactivation of multiple pathways that positively regulate senescence are required for immortalization. To identify these pathways in an unbiased manner, we performed DNA microarray analyses to assess the expression of 20,000 genes in human prostate epithelial cells (HPECs) passaged to senescence. These gene expression patterns were then compared with those of HPECs immortalized with the humanPapillomavirus 16 E7 oncoprotein. Senescent cells display gene expression patterns that reflect their nonproliferative, differentiated phenotype and express secretory proteases and extracellular matrix components. A comparison of genes transcriptionally up-regulated in senescence to those in which expression is significantly down-regulated in immortalized HPECs identified three genes: the chemokine BRAK,DOC1, and a member of the insulin-like growth factor axis,IGFBP-3. Expression of these genes is found to be uniformly lost in human prostate cancer cell lines and xenografts, and previously, their inactivation was documented in tumor samples. Thus, these genes may function in novel pathways that regulate senescence and are inactivated during immortalization. These changes may be critical not only in allowing cells to bypass senescence in vitrobut in the progression of prostate cancer in vivo.

Cited by (0)

Published, JBC Papers in Press, February 8, 2002, DOI 10.1074/jbc.M200373200

*

This work was supported by grants from the National Institutes of Health (CA76184-01 to D. F. J.), the University of Wisconsin Comprehensive Cancer Center (to D. F. J.), the Doris Duke Foundation (to J. D. B.), and the Kovitz Foundation (to J. D. B.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

210

The on-line version of this article (available at http://www.jbc.org) contains Supplemental Figs. 1–4.

Current address: Sugen, Inc., South San Francisco, CA 94080.